Potentially increased incidence of scaffold thrombosis in patients treated with Absorb BVS who terminated DAPT before 18 months
EuroIntervention 2017;13:e177-e184 published online ahead of print May 2017 published online e-edition June 2017. DOI: 10.4244/EIJ-D-17-00119
Cordula M. Felix1, MD; Georgios J. Vlachojannis2, MD, PhD; Alexander J.J. IJsselmuiden3, MD, PhD; Jiang M. Fam4, MD; Peter C. Smits2, MD, PhD; Wouter J. Lansink3, Msc; Roberto Diletti1, MD, PhD; Felix Zijlstra1, MD, PhD; Evelyn S. Regar1, MD, PhD; Eric Boersma1, PhD; Yoshinobu Onuma1, MD, PhD; Robert J.M. van Geuns1*, MD, PhD
1. Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; 2. Maasstad Hospital, Rotterdam, the Netherlands; 3. Albert Schweitzer Hospital, Dordrecht, the Netherlands; 4. National Heart Centre Singapore, Singapore
Aims: The aim of this study was to investigate the impact of dual antiplatelet therapy (DAPT) termination on late and very late scaffold thrombosis (ScT) in patients treated with the Abso
